other material
confidence high
sentiment neutral
materiality 0.60
Inovio prices $25M public offering of common stock and warrants
INOVIO PHARMACEUTICALS, INC.
- Gross proceeds of $25M from 14,285,715 shares and accompanying Series A/B warrants at $1.75/unit.
- Net proceeds expected ~$22.5M after underwriting discounts and expenses; closing on July 7, 2025.
- Underwriters have 30-day option for up to 2,142,857 additional shares and warrants.
- Series A warrants expire 12 months from issuance or 30 days after FDA acceptance of BLA for INO-3107.
- Series B warrants expire 5 years; Piper Sandler sole book-runner, Oppenheimer passive bookrunner.